Strong On High Relative Volume: Portola Pharmaceuticals (PTLA)
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
Trade-Ideas LLC identified
(
) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Portola Pharmaceuticals as such a stock due to the following factors:
- PTLA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $19.6 million.
- PTLA has traded 52,175 shares today.
- PTLA is trading at 3.93 times the normal volume for the stock at this time of day.
- PTLA is trading at a new high 7.20% above yesterday's close.
'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in PTLA with the Ticky from Trade-Ideas. See the FREE profile for PTLA NOW at Trade-Ideas
More details on PTLA:
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. Currently there are 2 analysts that rate Portola Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for Portola Pharmaceuticals has been 389,800 shares per day over the past 30 days. Portola has a market cap of $1.9 billion and is part of the health care sector and drugs industry. Shares are up 34.5% year-to-date as of the close of trading on Friday.
Analysis:
rates Portola Pharmaceuticals as a
. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow.
Highlights from the ratings report include:
- PORTOLA PHARMACEUTICALS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. For the next year, the market is expecting a contraction of 77.9% in earnings (-$3.20 versus -$1.80).
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 93.0% when compared to the same quarter one year ago, falling from -$18.55 million to -$35.79 million.
- Net operating cash flow has significantly decreased to -$23.42 million or 72.43% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- The revenue fell significantly faster than the industry average of 36.4%. Since the same quarter one year prior, revenues fell by 12.2%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
- Compared to other companies in the Biotechnology industry and the overall market, PORTOLA PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- You can view the full Portola Pharmaceuticals Ratings Report.
null